355 related articles for article (PubMed ID: 19670703)
21. Case of regional lymphomatoid papulosis confined to the periorbital areas.
Kim YJ; Rho YK; Yoo KH; Kim JY; Seo SJ; Hong CK; Moon NJ; Song KY
J Dermatol; 2009 Mar; 36(3):163-5. PubMed ID: 19335692
[TBL] [Abstract][Full Text] [Related]
22. The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis.
McQuitty E; Curry JL; Tetzlaff MT; Prieto VG; Duvic M; Torres-Cabala C
J Cutan Pathol; 2014 Feb; 41(2):88-100. PubMed ID: 24118002
[TBL] [Abstract][Full Text] [Related]
23. CD30-positive lymphoproliferative disorders arising after regional therapy for recurrent melanoma: a report of two cases and analysis of CD30 expression.
Gill K; Ariyan C; Wang X; Brady MS; Pulitzer M
J Surg Oncol; 2014 Sep; 110(3):258-64. PubMed ID: 24891295
[TBL] [Abstract][Full Text] [Related]
24. Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy.
Querfeld C; Kuzel TM; Guitart J; Rosen ST
Oncology (Williston Park); 2007 May; 21(6):689-96; discussion 699-700,. PubMed ID: 17564326
[TBL] [Abstract][Full Text] [Related]
25. Angioinvasive lymphomatoid papulosis: a new variant simulating aggressive lymphomas.
Kempf W; Kazakov DV; Schärer L; Rütten A; Mentzel T; Paredes BE; Palmedo G; Panizzon RG; Kutzner H
Am J Surg Pathol; 2013 Jan; 37(1):1-13. PubMed ID: 23026936
[TBL] [Abstract][Full Text] [Related]
26. Pathobiology of CD30+ cutaneous T-cell lymphomas.
Kadin ME
J Cutan Pathol; 2006 Feb; 33 Suppl 1():10-7. PubMed ID: 16412208
[TBL] [Abstract][Full Text] [Related]
27. Potential involvement of Notch1 signalling in the pathogenesis of primary cutaneous CD30-positive lymphoproliferative disorders.
Kamstrup MR; Ralfkiaer E; Skovgaard GL; Gniadecki R
Br J Dermatol; 2008 Apr; 158(4):747-53. PubMed ID: 18241263
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea.
Kim YC; Yang WI; Lee MG; Kim SN; Cho KH; Lee SJ; Lee MW; Koh JK
Int J Dermatol; 2006 Nov; 45(11):1312-6. PubMed ID: 17076712
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment.
Kempf W; Kerl K; Mitteldorf C
Semin Cutan Med Surg; 2018 Mar; 37(1):24-29. PubMed ID: 29719017
[TBL] [Abstract][Full Text] [Related]
30. Histopathological aspects and differential diagnosis of CD8 positive lymphomatoid papulosis.
Marschalkó M; Gyöngyösi N; Noll J; Károlyi Z; Wikonkál N; Hársing J; Kuroli E; Csomor J; Matolcsy A; Sarolta K; Szepesi Á
J Cutan Pathol; 2016 Nov; 43(11):963-973. PubMed ID: 27461449
[TBL] [Abstract][Full Text] [Related]
31. Differences in survivin location and Bcl-2 expression in CD30+ lymphoproliferative disorders of the skin compared with systemic anaplastic large cell lymphomas: an immunohistochemical study.
Goteri G; Simonetti O; Rupoli S; Piccinini G; Rubini C; Stramazzotti D; Fazioli F; Capomagi C; Leoni P; Offidani AM; Lo Muzio L
Br J Dermatol; 2007 Jul; 157(1):41-8. PubMed ID: 17484779
[TBL] [Abstract][Full Text] [Related]
32. Loss of expression of 5-hydroxymethylcytosine in CD30-positive cutaneous lymphoproliferative disorders.
De Souza A; Tinguely M; Pfaltz M; Burghart DR; Kempf W
J Cutan Pathol; 2014 Dec; 41(12):901-6. PubMed ID: 25353265
[TBL] [Abstract][Full Text] [Related]
33. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
Di Raimondo C; Parekh V; Song JY; Rosen ST; Querfeld C; Zain J; Martinez XU; Abdulla FR
Curr Hematol Malig Rep; 2020 Aug; 15(4):333-342. PubMed ID: 32435988
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.
Ferreira CR; Zhao S; Sanches JA; Miyashiro D; Cury-Martins J; Azevedo RS; Zerbini MCN; Natkunam Y; Gratzinger D
Diagn Pathol; 2019 Oct; 14(1):115. PubMed ID: 31640798
[TBL] [Abstract][Full Text] [Related]
35. A Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder Arising in a Patient With Multiple Myeloma and Cutaneous Amyloidosis.
Romano RC; Cohen DN; Howard MT; Wieland CN
Am J Dermatopathol; 2016 May; 38(5):388-92. PubMed ID: 26981738
[TBL] [Abstract][Full Text] [Related]
36. Selective IgM deficiency in CD30+ cutaneous lymphoproliferative disorder.
Saini S; Dettore AJ; Bhambhani KJ; Buck S; Poulik J; Savaşan S
J Pediatr Hematol Oncol; 2011 May; 33(4):e156-9. PubMed ID: 21516014
[TBL] [Abstract][Full Text] [Related]
37. Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders.
Kadin ME
Oncology (Williston Park); 2009 Nov; 23(13):1158-64. PubMed ID: 20043465
[TBL] [Abstract][Full Text] [Related]
38. SATB1 Defines a Subtype of Cutaneous CD30
Sun J; Yi S; Qiu L; Fu W; Wang A; Liu F; Wang L; Wang T; Chen H; Wang L; Kadin ME; Tu P; Wang Y
J Invest Dermatol; 2018 Aug; 138(8):1795-1804. PubMed ID: 29510190
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous CD30 positive lymphoproliferative disorders with coexistent epithelial neoplasms: Report of two cases.
Newland KM; McCormack CJ; Prince HM; Lade S
Australas J Dermatol; 2015 Nov; 56(4):e83-7. PubMed ID: 25330922
[TBL] [Abstract][Full Text] [Related]
40. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.
Drakos E; Leventaki V; Schlette EJ; Jones D; Lin P; Medeiros LJ; Rassidakis GZ
Am J Surg Pathol; 2007 Mar; 31(3):447-53. PubMed ID: 17325487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
